The
United Kingdom Prostate Cancer Therapeutics Market is anticipated to grow
significantly in the projected period of 2028. Prostate cancer is one of the
most common types of cancer affecting men globally, including the United
Kingdom. Over the years, significant progress has been made in the development
of effective therapies to combat this disease. The United Kingdom has a robust
healthcare system that prioritizes cancer care, including prostate cancer.
According to the World Cancer Research Fund, 55,068 new prostate cancer cases
were reported in the United Kingdom in 2019, with a one-year survival rate of
97.2% and a five-year survival rate of 87.9%. With a strong emphasis on early
detection and timely treatment, the country has witnessed improved survival
rates and better patient outcomes.
Prostate
cancer therapeutics encompass a range of approaches, including surgery,
radiation therapy, hormone therapy, and targeted therapies. In recent years,
the UK has witnessed notable advancements in prostate cancer therapeutics. One
significant breakthrough has been the development and approval of novel
targeted therapies. These therapies aim to disrupt specific molecular pathways
involved in prostate cancer progression, offering more personalized and precise
treatment options for patients. Targeted therapies, such as androgen receptor
inhibitors and PARP inhibitors, have demonstrated promising results in clinical
trials, extending survival and improving the quality of life for patients.
Furthermore,
the advent of immunotherapy has opened new avenues in prostate cancer
treatment. Immune checkpoint inhibitors, which unleash the body's immune system
to recognize and attack cancer cells, have shown encouraging results in
late-stage prostate cancer. Ongoing research and clinical trials are exploring the
potential of combining immunotherapy with other treatment modalities to enhance
efficacy, contributing to the growth of the Prostate Cancer Therapeutics Market
in the United Kingdom.
In
addition, the aging population is also driving demand for Prostate Cancer
Therapeutics. As people age, their bodies become less efficient, and the
chances of prostate cancer increase. This has led to an increase in demand for prostate
cancer therapeutics that can help to recover from prostate cancer. According to
the Office for National Statistics, the statistical results for 2021 show that
the population of England and Wales has continued to age, and there are now
more people than ever in older age categories. In comparison to 16.4% at the
time of the previous census in 2011, almost 11 million people, or 18.6% of the
total population, were 65 years of age or older. This comprised 527,900
individuals who were at least 90 years old.
Growing Prevalence of Prostate cancer will spur the Demand
for Prostate Cancer Therapeutics
With the rising prevalence of this disease, the demand
for effective prostate cancer therapeutics in the UK has witnessed a notable
surge. Prostate cancer is the most commonly diagnosed cancer among men in the
UK, and its prevalence is expected to continue increasing in the coming years.
Prostate cancer is a malignant tumor that develops in the prostate gland, which
is a part of the male reproductive system. Over the past few decades, the
incidence of prostate cancer has been steadily increasing in the United
Kingdom. Together with studies on migrants, the tendency of prostate cancer
incidence to be significantly higher in Western nations (such as the UK)
suggests that lifestyle and/or environmental factors, such as diet, may play a
significant role in determining prostate cancer risk.
However, there is currently a lack of knowledge
regarding the lifestyle factors that may cause prostate cancer. Additionally,
if a man has a first-degree relative (father or brother) who was diagnosed with
prostate cancer at a young age, his risk of getting the disease rises. Factors
such as an aging population, changing lifestyle patterns, and improved
screening and diagnostic techniques have contributed to the rising number of
prostate cancer cases. Age is a significant risk factor for prostate cancer,
and as the UK population ages, the number of men at risk also increases. The
increasing life expectancy and changing demographics have played a pivotal role
in the prevalence of prostate cancer. According to Prostate Cancer UK, prostate
cancer claims the lives of one man every 45 minutes, or more than 12,000 men
annually.
On average, more than 52,000 men are given prostate
cancer diagnoses each year, or 143 men each day. Treatment decisions depend on
various factors such as the stage and aggressiveness of the cancer, the patient's
overall health, and their preferences. The evolving landscape of prostate
cancer treatment has witnessed the emergence of novel therapies, including
immunotherapies and precision medicine approaches, which aim to improve patient
outcomes and quality of life. Pharmaceutical companies and research
institutions are investing heavily in the development of new prostate cancer
therapeutics. Clinical trials are underway to evaluate the efficacy and safety
of these novel treatment options, providing hope for better outcomes for
prostate cancer patients, which is expected to propel the growth of the United
Kingdom Prostate Cancer Therapeutics Market.
Download Free Sample Report
Expanding Novel Screening and Diagnostic Technologies Propel UK
Prostate Cancer Therapeutics Market
The United Kingdom has been investing in the development of its
health systems to improve patient care and streamline operations. The
healthcare industry already utilizes robots, AI, and other automation tools.
One of the most promising advancements in prostate cancer screening is the
integration of biomarkers and genetic testing. Novel tests, such as the
Prostate Health Index (phi) and 4Kscore, combine multiple biomarkers to provide
a more accurate assessment of prostate cancer risk. These tests help reduce
unnecessary biopsies and improve patient outcomes. Additionally, multiparametric
magnetic resonance imaging (mpMRI) has gained significant traction in the
United Kingdom for prostate cancer detection. mpMRI allows for high-resolution
visualization of the prostate gland, aiding in the identification of suspicious
lesions.
By integrating mpMRI with targeted biopsies, clinicians can enhance
the accuracy of cancer diagnosis while minimizing patient discomfort.
Furthermore, expanding and developing public health initiatives, implementing
new medical technologies, and making socioeconomic and educational advancements
have significantly improved the country. As a result, patterns of morbidity and
mortality, as well as other indicators of health status like average life
expectancy at birth, have significantly improved. There has been a surge in
research and development activities in the United Kingdom's Prostate Cancer
Therapeutics market. According to the Office for National Statistics, in
2021, the total current healthcare expenditure increased by 7.1% in real terms,
compared to 10.0% in 2020, after accounting for the effects of inflation on the
economy as a whole.
Recent Developments
- In April 2023, a new
240mg strength tablet of Janssen Pharmaceutical Companies' ERLEADA
(apalutamide), a medication for prostate cancer, will be made available.
ERLEADA is an androgen receptor inhibitor (ARI) prescribed for the
treatment of men with metastatic castration-sensitive prostate cancer
(mCSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).
Patients now have the option to take the medication once daily in a single
tablet form, thanks to the introduction of the higher-strength tablet. Previously,
the medication was only accessible as a 60 mg tablet, which needed to be
taken four times per day.
- In February 2023,
results from the Phase 3 TALAPRO-2 study of the oral PARP inhibitor
TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) in men with
metastatic castration-resistant prostate cancer (mCRPC), with or without
homologous recombinant DNA therapy, showed a statistically significant and
clinically meaningful improvement in radiographic progression-free
survival (rPFS) compared to placebo plus XTANDI. Additionally, Pfizer's
supplemental new drug application (sNDA) for TALZENNA in combination with
XTANDI for the treatment of men with mCRPC has been given Priority Review
by the U.S. Food and Drug Administration (FDA). When there are no adequate
treatments available, the FDA will give medicines that have the potential
to make significant advances in treatment a priority review.
Market Segmentation
United Kingdom Prostate
Cancer Therapeutics Market is segmented into Treatment, End User, Region and
Competitive Landscape. Based on Treatment, the market is divided into Hormonal
Therapy, Immunotherapy, Targeted Therapy, Chemotherapy and Others. Based on End
User, the Market is categorized into Hospital pharmacies, Retail pharmacies,
Online pharmacies. Based on Region, the United Kingdom Prostate Cancer
Therapeutics Market is segmented into Scotland, South-East, London, South-West,
East-Anglia, Yorkshire & Humberside, and East Midlands.
Company Profiles
Johnson
& Johnson, Astellas Pharma Inc, Ipsen Pharma, Sanofi, Bayer AG, AstraZeneca,
Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, GlaxoSmithKline plc are
some of the key players in the United Kingdom Prostate Cancer Therapeutics market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
volume forecasting, Company shares, competitive landscape, growth factors,
and trends
|
|
Segments covered
|
Treatment
End User
Region
|
|
Country scope
|
Scotland,
South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and
East Midlands
|
|
Key companies profiled
|
Johnson
& Johnson, Astellas Pharma Inc, Ipsen Pharma, Sanofi, Bayer AG,
AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott,
GlaxoSmithKline plc
|
|
Customization scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing and purchase
options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF
and Excel through Email (We can also provide the editable version of the
report in PPT/Word format on special request)
|
Report Scope:
In this report, United Kingdom Prostate Cancer
Therapeutics Market has been segmented into the following categories, in addition
to the industry trends, which have also been detailed below:
- United Kingdom Prostate
Cancer Therapeutics Market, By Treatment:
- Hormonal Therapy
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Others
- United Kingdom Prostate
Cancer Therapeutics Market, By End User:
- Hospital
pharmacies
- Retail pharmacies
- Online pharmacies
- United Kingdom Prostate
Cancer Therapeutics Market, By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire &
Humberside
- East Midlands
Competitive landscape
Company Profiles: Detailed analysis of the major companies in United
Kingdom Prostate Cancer Therapeutics market.
Available Customizations:
With the given market data, TechSci Research offers customizations
according to a company’s specific needs. The following customization options are
available for the report:
Company
Information
- Detailed analysis
and profiling of additional market players (up to five).
United Kingdom Prostate Cancer
Therapeutics Market is an upcoming report to be released soon. If you wish an early
delivery of this report or want to confirm the date of release, please contact
us at [email protected].